Evicenter
P&T meetings

Saroglitazar

Primary biliary cholangitis

Manufacturer
Zydus Therapeutics
Regulatory submission
NDA submitted by May 2026
Last updated
81 sources

Economic information and modeling reportBudget impact model

Model outcomes

2 evidence topics · 1 source

Willingness-to-pay thresholds
ParameterQuoted value
Lower threshold, euros per QALY“€25,000”
Higher threshold, euros per QALY“€30,000”
Expected net monetary benefit across modeled subgroups“negative”